|
KMID : 1130320070500090823
|
|
Korean Journal of Pediatrics
2007 Volume.50 No. 9 p.823 ~ p.834
|
|
|
The management and treatment of chronic hepatitis B in Korean children
|
|
Choe Byung-Ho
|
|
|
Abstract
|
|
|
|
Interferon (IFN) alpha has been the first line therapy of chronic hepatitis B in children, but HBeAg seroconversion occurred in 26% of treated children compared to 11% of controls in multinational randomized controlled study. Recently, lamivudine was shown to be a potent inhibitor of Hepatitis B virus (HBV) reproduction both in HBeAg positive and in HBeAg negative (the pre-core mutant form) chronic hepatitis in randomized studies worldwide. Lamivudine therapy led to considerable improvement in the seroconversion rate of HBeAg in children with chronic hepatitis B, though long-term therapy resulted in the expansion of lamivudine-resistant mutant viruses. Combination therapy with lamivudine plus alpha-IFN does not seem to improve HBe Ag seroconversion. Above all, the most effective way to prevent hepatitis B is universal HBV vaccination.
|
|
|
KEYWORD
|
|
|
Chronic Hpatitis B, Management, Treatment, Interferon, Lamivudine, Children
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|